Bausch Health Reports Strong Q3 2026 Results with Record Adjusted EBITDA
Bausch Health (BHC) reported robust third-quarter 2026 financial results, driven by significant growth in its core healthcare segments. Consolidated revenues reached $2.94 billion, an 8% increase on an organic basis. A major highlight was the company's adjusted EBITDA (excluding Bausch + Lomb), which surpassed the $1 billion milestone for the first time in a single quarter, reaching $1.022 billion. The Salix segment saw a 16% revenue increase fueled by Xifaxan demand, while Solta Medical grew 18%. Despite these gains, management warned of upcoming headwinds in Q4 due to Medicare pricing adjustments for Xifaxan and softening consumer confidence in the Chinese market affecting Solta Medical. Nevertheless, the company raised its full-year 2026 revenue guidance and demonstrated strong balance sheet management through $521 million in net debt reduction during the quarter.
Topics: Debt Reduction EBITDA Milestone Financial Guidance Revenue Growth Xifaxan Performance
Read the full article at Motley Fool
Part of the story Bausch Health Reports Strong Q3 2026 Results with Record Adjusted EBITDA (8 articles)